Last $42.97 USD
Change Today -0.12 / -0.28%
Volume 4.3M
ABT On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
London
Sao Paulo
Frankfurt
As of 4:01 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months

Announced 07/14/14
5.27B for Abbott Laboratories, Non-U.S. Developed Markets Specialty and Branded Generics Business
Merger/Acquisition

Mylan, Inc. (NasdaqGS:MYL) entered into a business transfer agreement to acquire non-U.S. developed markets specialty and branded generics business of Abbott Laboratories (NYSE:ABT) for approximately $5.3 billion on July 13, 2014. The assets are being acquired on a debt-free basis. In the transaction, Abbott will transfer the assets to Mylan in consideration for 105 million Mylan ordinary shares, representing 21% stake and Mylan will hold 71% stake. Under the agreement, ...
Read More


ABT's price was unchanged after the transaction was announced on 07/14/14.
Investor / Buyer
Mylan, Inc.
Creditor / Lender
Abbott Laboratories
 
Announced 06/23/14
631.00M for GardenHills OOO
Merger/Acquisition

Abbott Laboratories (NYSE:ABT) signed a definitive agreement to acquire GardenHills OOO for approximately $630 million on June 23, 2014. Under the terms of the agreement, Abbott will acquire Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between approximately $395 million to $495 million depending on GardenHills' share ownership of Veropharm at time of close. If Garden Hills owns 100% of the shares of Veropharm at that ...
Read More


ABT's price was unchanged after the transaction was announced on 06/23/14.
Investor / Buyer
Abbott Laboratories
Legal Advisor
Hogan Lovells (CIS)
 
Announced 01/27/14
Aviir Inc.
Bankruptcy

Aviir, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Central District of California on January 27, 2014. The debtor listed its assets of $3.70 million and liabilities of $13.62 million. The largest unsecured creditors include Bay City Capital Fund IV Co-Investment Fund, L.P., Merck Global Health Innovation Fund, LLC, Abbott Laboratories, Paragon Biomedical, Inc., Quansys Biosciences, Inc., Stradling Yocca Carlson & ...
Read More


ABT's price was unchanged after the transaction was announced on 01/27/14.
Creditor / Lender
Abbott Laboratories
Aerotek Inc.
Bay City Capital Fund IV Co-Investment Fund, L.P
Global Health Innovation Fund, LLC
Paragon Biomedical, Inc.
Quansys Biosciences, Inc.
Salesforce.com, Inc
Stanford University
Starlims Corporation
Stradling Yocca Carlson & Rauth, P.C.
Legal Advisor
Dorsey & Whitney LLP
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $42.97 USD -0.12

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.48 USD +0.43
Bristol-Myers Squibb Co $49.32 USD +0.20
Danaher Corp $75.61 USD -0.19
Eli Lilly & Co $64.25 USD +0.53
Medtronic Inc $63.37 USD +0.66
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 31.1x
Price/Sales 3.0x
Price/Book 2.8x
Price/Cash Flow 20.7x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.